Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Patrick K. Reville; Hagop M. Kantarjian; Farhad Ravandi; Elias Jabbour; Courtney D. DiNardo; Naval Daver; Naveen Pemmaraju; Maro Ohanian; Yesid Alvarado; Lianchun Xiao; Gheath Alatrash; Sanam Loghavi; Caitlin R. Rausch; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Tapan M. Kadia

doi:10.1038/s41408-021-00453-z

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Patrick K. Reville, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Maro Ohanian, Yesid Alvarado, Lianchun Xiao, Gheath Alatrash, Sanam Loghavi, Caitlin R. Rausch, Gautam Borthakur, Marina Konopleva, Jorge Cortes, Tapan M. Kadia

Research output: Contribution to journal › Letter › peer-review

24 Scopus citations

Original language	English (US)
Article number	60
Journal	Blood cancer journal
Volume	11
Issue number	3
DOIs	https://doi.org/10.1038/s41408-021-00453-z
State	Published - Mar 2021

ASJC Scopus subject areas

Hematology
Oncology

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1038/s41408-021-00453-z

Cite this

Reville, P. K., Kantarjian, H. M., Ravandi, F., Jabbour, E., DiNardo, C. D., Daver, N., Pemmaraju, N., Ohanian, M., Alvarado, Y., Xiao, L., Alatrash, G., Loghavi, S., Rausch, C. R., Borthakur, G., Konopleva, M., Cortes, J., & Kadia, T. M. (2021). Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood cancer journal, 11(3), Article 60. https://doi.org/10.1038/s41408-021-00453-z

Reville, PK , Kantarjian, HM , Ravandi, F , Jabbour, E , DiNardo, CD , Daver, N , Pemmaraju, N , Ohanian, M , Alvarado, Y , Xiao, L , Alatrash, G , Loghavi, S, Rausch, CR, Borthakur, G, Konopleva, M, Cortes, J & Kadia, TM 2021, 'Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study', Blood cancer journal, vol. 11, no. 3, 60. https://doi.org/10.1038/s41408-021-00453-z

@article{ee1ee20156f5420a977a0ae6fbe1fbe3,

title = "Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study",

author = "Reville, {Patrick K.} and Kantarjian, {Hagop M.} and Farhad Ravandi and Elias Jabbour and DiNardo, {Courtney D.} and Naval Daver and Naveen Pemmaraju and Maro Ohanian and Yesid Alvarado and Lianchun Xiao and Gheath Alatrash and Sanam Loghavi and Rausch, {Caitlin R.} and Gautam Borthakur and Marina Konopleva and Jorge Cortes and Kadia, {Tapan M.}",

note = "Funding Information: The authors thank the patients and their families who participated in this clinical trial. We also thank the research coordinators, research nurses, advance practice providers, and other staff for their support of this clinical trial. This work was supported by Bristol-Myers Squibb, the MD Anderson Cancer Center Leukemia Support Grant CA016672, the MD Anderson Cancer Center Leukemia SPORE CA100632, and the MD Anderson Moon Shots Program. PKR is supported by a T32 grant from the NIH (T32CA009666). This work was previously presented at EHA 2017 and ASCO 2018.",

year = "2021",

month = mar,

doi = "10.1038/s41408-021-00453-z",

language = "English (US)",

volume = "11",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Nivolumab maintenance in high-risk acute myeloid leukemia patients

T2 - a single-arm, open-label, phase II study

AU - Reville, Patrick K.

AU - Kantarjian, Hagop M.

AU - Ravandi, Farhad

AU - Jabbour, Elias

AU - DiNardo, Courtney D.

AU - Daver, Naval

AU - Pemmaraju, Naveen

AU - Ohanian, Maro

AU - Alvarado, Yesid

AU - Xiao, Lianchun

AU - Alatrash, Gheath

AU - Loghavi, Sanam

AU - Rausch, Caitlin R.

AU - Borthakur, Gautam

AU - Konopleva, Marina

AU - Cortes, Jorge

AU - Kadia, Tapan M.

N1 - Funding Information: The authors thank the patients and their families who participated in this clinical trial. We also thank the research coordinators, research nurses, advance practice providers, and other staff for their support of this clinical trial. This work was supported by Bristol-Myers Squibb, the MD Anderson Cancer Center Leukemia Support Grant CA016672, the MD Anderson Cancer Center Leukemia SPORE CA100632, and the MD Anderson Moon Shots Program. PKR is supported by a T32 grant from the NIH (T32CA009666). This work was previously presented at EHA 2017 and ASCO 2018.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85102710455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102710455&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00453-z

DO - 10.1038/s41408-021-00453-z

M3 - Letter

C2 - 33731681

AN - SCOPUS:85102710455

SN - 2044-5385

VL - 11

JO - Blood cancer journal

JF - Blood cancer journal

IS - 3

M1 - 60

ER -

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this